Immunic, Inc.
Immunic, Inc. (IMUX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
imux · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Immunic, Inc. (IMUX) measures how much investors pay for each dollar of the company's trailing earnings. IMUX's current PE ratio of N/A is calculated by dividing its stock price of $12.06 by its TTM earnings per share of -$3.46.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Immunic, Inc.You IMUX | $119M | N/A | — | -$3.46 |
 Adicet Bio, Inc. ACET | $67M | N/A | — | -$16.95 |
 Acrivon Therapeutics, Inc. Common Stock ACRV | $44M | N/A | — | -$2.02 |
 Biomea Fusion, Inc. BMEA | $68M | N/A | — | -$1.18 |
 Cibus, Inc. CBUS | $56M | N/A | — | -$0.28 |
 Lite Strategy, Inc. LITS | $26M | N/A | — | -$2.39 |
 PMV Pharmaceuticals, Inc. PMVP | $58M | N/A | — | -$1.48 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-6.24 | — | |
2024-12-31 FY2024 | — | $-10.03 | — | |
2023-12-31 FY2023 | — | $-21.12 | — | |
2022-12-31 FY2022 | — | $-37.84 | — | |
2021-12-31 FY2021 | — | $-39.30 | — | |
2020-12-31 FY2020 | — | $-28.10 | — | |
2019-12-31 FY2019 | — | $-45.10 | — | |
2018-12-31 FY2018 | — | $-391.56 | — | |
2017-12-31 FY2017 | — | $-522.62 | — | |
2016-12-31 FY2016 | — | $-522.10 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Immunic, Inc. (IMUX) measures how much investors pay for each dollar of the company's trailing earnings. IMUX's current PE ratio of N/A is calculated by dividing its stock price of $12.06 by its TTM earnings per share of -$3.46.
Frequently asked questions
IMUX pe ratio · 6 questionsIMUX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $12.06 and TTM EPS of -$3.46. Data sourced from Financial Modeling Prep via IMUX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Immunic, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09